Denmark-based Novo Nordisk has provided some new details about a potential successor to Ozempic. Phone call with investors on Tuesday. Sales of the company’s current blockbuster product slimming pill Wegovy, It continued to rise in the third quarter, exceeding Wall Street expectations. Millennial-skewed telehealth platform Hims & Hers (THEM) announced this week that it will begin rolling out an offer to its customers. generic version of liraglutidean old GLP-1 weight loss drug next year.

Check out these stories and this week’s other top pharmaceutical news.

FDA wants to ban a common ingredient in over-the-counter cold and allergy medications

The U.S. Food and Drug Administration (FDA) announced today that it has proposed a new rule to halt the use of an ingredient in popular over-the-counter (OTC) cold and allergy medications. The rule would remove oral phenylephrine from the list of approved active ingredients that can be used in over-the-counter medications such as NyQuil (PG), Benadryl (JNJ) and Mucinex. After reviewing available data, the agency determined that phenylephrine does not actually work as a nasal decongestant when taken orally.

Read more

A new, more powerful Ozempic is coming. Here’s what you need to know

Novo Nordisk (NVO) provided some new details about Ozempic’s potential successor during a meeting. Meeting with investors on Tuesday. The Danish pharmaceutical giant answered various questions from interested analysts regarding the effectiveness, safety and supply chain of the new generation GLP-1 drug ÇağrıSema.

Read more

Hims & Hers will start selling a generic weight-loss pill

Millennial-skewed telehealth platform Hims & Hers (THEM) announced this week that it will begin offering customers a generic version of liraglutide, an older GLP-1 weight-loss drug, next year. The news comes at a time when some patients are still trying to fill prescriptions for the most advanced brand-name GLP-1 treatments on the market, such as Zepbound, Wegovy and Ozempic.

Read more

Wegovy sales are currently killing Novo Nordisk

Novo Nordisk’s sales (NVO) blockbuster slimming pill Wegovy It continues to rise, beating Wall Street’s expectations. The Danish pharmaceutical giant released its third-quarter earnings report early Wednesday and said Wegovy’s sales will skyrocket by 79% to 17.3 billion Danish kroner ($1.37 billion) in the third quarter of 2024. It was reported that it reached ($2.5 billion). in the same period last year. The drug beat analysts’ expectations for $2.3 billion, according to FactSet’s consensus estimate.

Read more

A new weight-loss drug could overcome Ozempic’s side-effect problem

Denmark-based drugmaker Zealand Pharma said on Tuesday that its experimental weight-loss drug could help patients lose weight with fewer side effects than existing anti-obesity drugs on the market. The company said only one-third of patients taking doses of up to 4.8 milligrams of the drug petrelintide during an early-stage clinical trial experienced nausea; This is one of the most common side effects of popular GLP-1 weight loss medications. . Zealand announced the new finding at the ObesityWeek industry conference in San Antonio.

Read more

Ozempic maker Novo Nordisk is working on a once-a-month weight loss pill

Novo Nordisk (NVOWegovy and Ozempic, makers of blockbuster weight loss and diabetes drugs, have signed a deal with Denmark-based Ascendis Pharma (ASND) to take advantage of the latter’s advanced drug delivery technology. The partnership aims to accelerate the development of a long-acting, monthly GLP-1 drug. Current GLP-1 drugs on the market are administered as injections once a week.

Read more

New slimming pill surpasses Novo Nordisk’s version

Viking Treatments (VKTX) released new clinical trial data earlier this week for its experimental weight-loss drugs, which include a highly anticipated oral pill. The company reported that in a small phase 1 clinical study, patients taking a 100-milligram daily dose of Viking weight loss pills lost an average of up to 100 milligrams of weight. 6.8% of body weight for 28 days when adjusted for placebo recipients. William Blair analyst Andy Hsieh noted Monday that Viking’s results beat Wall Street’s expectations and outperformed Novo Nordisk’s experimental weight-loss pill amycretin.

Read more

What can’t Ozempic and other weight loss medications treat?

It seems like every day a new study emerges that makes a connection Ozempic and similar drugs to new health benefits. Ozempic is part of a class of medications known as GLP-1 drugs that mimic gut hormones that help regulate blood sugar and suppress appetite. These drugs have become popular effective in treating obesity and type 2 diabetes, but researchers are uncovering even more potential uses. Take a look at the latest research revealing surprising new uses for GLP-1 drugs.

Read more

For the latest news, Facebook, excitement And instagram.